Yescarta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advances in genetic engineering technologies, increasing incidence of hematologic malignancies, regulatory approvals of car-t therapies, expansion of specialized cancer treatment centers, early success in refractory lymphoma treatment.

The growth in the forecast period can be attributed to expansion into additional cancer indications, rising investments in next-generation car constructs, growing focus on manufacturing scalability, increasing adoption in earlier treatment lines, development of cost-optimized cell therapy processes. Major trends in the forecast period include expanding adoption of car-t cell therapies in oncology, rising focus on personalized cancer treatments, growing investment in cell and gene therapy platforms, increased use of autologous immunotherapies, enhanced emphasis on long-term remission outcomes.

The increasing incidence of leukemia is expected to drive the growth of the Yescarta market. Leukemia is a cancer that affects the blood and bone marrow, resulting in the abnormal production of white blood cells. Its rising incidence is attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and improved diagnostic techniques. Yescarta, an advanced CAR T-cell therapy, transforms leukemia treatment by reprogramming a patient’s immune cells to recognize and destroy cancerous cells, offering improved outcomes for patients. For example, in 2024, the American Cancer Society, a US-based non-profit organization, reported 62,770 new cases of leukemia, up from 59,610 cases in 2023. Therefore, the increasing incidence of leukemia is driving the Yescarta market.

The growing number of clinical trials is expected to propel the Yescarta market. Clinical trials are structured research studies involving human participants to evaluate the safety, efficacy, and optimal use of new treatments before broad approval. The increase in clinical trials is driven by the rising prevalence of chronic and rare diseases, prompting pharmaceutical and biotech companies to develop and test new therapies. Clinical trials support Yescarta by generating evidence on safety and efficacy, facilitating regulatory approvals, and increasing adoption by physicians and patients. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical trials in the UK rose for the second consecutive year, from 411 in 2022 to 426 in 2023. Therefore, the growing number of clinical trials is driving the Yescarta market.

The rising demand for personalized medicine is expected to boost the Yescarta market. Personalized medicine tailors disease prevention, diagnosis, and treatment to an individual’s genetic, environmental, and lifestyle factors. The growing demand is driven by the prevalence of chronic and genetic diseases, which require customized therapies to improve outcomes and minimize side effects. Yescarta benefits from personalized medicine by providing targeted CAR T-cell therapies tailored to each patient’s genetic and tumor profile, enhancing treatment efficacy and outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022, including seven cancer drugs. Therefore, the rising demand for personalized medicine is driving the Yescarta market.

Major companies operating in the yescarta market are Kite Pharma Inc. (a subsidiary of Gilead Sciences Inc.)

North America was the largest region in the yescarta market in 2025. The regions covered in the yescarta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yescarta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the yescarta market by increasing costs of imported viral vectors, cell processing equipment, cryopreservation systems, and specialized logistics required for autologous CAR-T manufacturing. North America and Europe are significantly affected due to complex cross-border supply chains, while Asia-Pacific faces higher costs in technology transfer and localized production. These tariffs raise overall therapy manufacturing expenses and can impact treatment accessibility. At the same time, they are encouraging domestic cell therapy manufacturing, regional production hubs, and investments in localized gene therapy infrastructure.

The yescarta market research report is one of a series of new reports that provides yescarta market statistics, including yescarta industry global market size, regional shares, competitors with a yescarta market share, detailed yescarta market segments, market trends and opportunities, and any further data you may need to thrive in the yescarta industry. This yescarta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Yescarta (axicabtagene ciloleucel) is an autologous CAR-T cell therapy used to treat certain hematologic cancers by modifying a patient’s own T cells to target CD19 on malignant B cells. It is specifically indicated for relapsed or refractory large B-cell lymphoma (LBCL) and primary mediastinal B-cell lymphoma in adults.

The main indications for Yescarta include large B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia (ALL), and follicular lymphoma. Large B-cell lymphoma (LBCL) is an aggressive non-Hodgkin lymphoma that originates in the lymphatic system. Yescarta is distributed through hospitals, specialty clinics, and online pharmacies, and is used by adult and geriatric patients.

The yescarta market consists of sales of cell-based therapies and intravenous (IV) infusion. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.